Benzinga · Sep 18, 2026
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
CA
AMEX · CATX
Perspective Therapeutics, Inc.
Healthcare · Medical - Devices
$2.57
Down-$0.21 (-8.17%)
Updated Oct 6, 2026, 9:41 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 200.3M
- P/E ratio
- -1.68
- Dividend yield
- 0.00%
- 52-week range
- $1.96 – $6.16
- Volume
- 3.56M
- Avg. volume
- 1.55M
Price performance · CATX
CATX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CATX closed at $2.57 after 20 trading sessions, down 17.63% for the selected period.
- Last close
- $2.57
- Period change
- -17.63%
- Period low
- $2.50
- Period high
- $3.12
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $2.75 | $2.82 | $2.48 | $2.57 | 3.56M |
| Oct 2, 2026 | $2.77 | $2.82 | $2.685 | $2.76 | 2.62M |
| Oct 1, 2026 | $2.71 | $2.775 | $2.66 | $2.72 | 1.54M |
| Sep 30, 2026 | $2.64 | $2.775 | $2.55 | $2.75 | 1.67M |
| Sep 29, 2026 | $2.52 | $2.62 | $2.49 | $2.62 | 1.54M |
| Sep 28, 2026 | $2.50 | $2.575 | $2.46 | $2.50 | 1.5M |
| Sep 25, 2026 | $2.50 | $2.525 | $2.45 | $2.52 | 1.8M |
| Sep 24, 2026 | $2.58 | $2.59 | $2.44 | $2.50 | 1.7M |
| Sep 23, 2026 | $2.89 | $2.92 | $2.50 | $2.62 | 3.16M |
| Sep 22, 2026 | $3.00 | $3.02 | $2.814 | $2.96 | 5.15M |
| Sep 21, 2026 | $2.94 | $3.03 | $2.895 | $2.97 | 2.11M |
| Sep 18, 2026 | $2.89 | $2.94 | $2.77 | $2.88 | 11.64M |
| Sep 17, 2026 | $2.76 | $2.92 | $2.74 | $2.88 | 1.17M |
| Sep 16, 2026 | $2.73 | $2.75 | $2.62 | $2.70 | 1.58M |
| Sep 15, 2026 | $2.88 | $2.89 | $2.66 | $2.73 | 1.47M |
| Sep 14, 2026 | $2.81 | $2.96 | $2.79 | $2.92 | 2.02M |
| Sep 11, 2026 | $2.77 | $2.825 | $2.665 | $2.81 | 2.02M |
| Sep 10, 2026 | $2.96 | $3.01 | $2.75 | $2.77 | 1.58M |
| Sep 9, 2026 | $3.07 | $3.1075 | $2.96 | $2.99 | 1.5M |
| Sep 8, 2026 | $3.12 | $3.18 | $3.02 | $3.12 | 1.06M |
Latest CATX news
The latest Smart Investors Daily articles mentioning CATX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CATX research
Overview
Company profile and research snapshot.
Company profile
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 18, 2026 | William Blair | Outperform | — |
| Sep 15, 2026 | Wedbush | Outperform | — |
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 14, 2026 | B of A Securities | Neutral | — |
| Aug 11, 2026 | Piper Sandler | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 18, 2026
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.
Benzinga · Sep 15, 2026
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
Yahoo · Sep 14, 2026
Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
SEATTLE, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced a clinical trial collaboration agreement with Merck (NYSE: MRK), known as MSD outside of the United States and Canada. The agreement supports the evaluation of Perspective’s targeted alpha-particle therapy [212Pb]PSV359 in com
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
